EC authorisation granted to kidney disease treatment Kinpeygo

The treatment was developed by Calliditas and will be marketed by Stada

The European Commission (EC) has granted conditional marketing authorisation for Kinpeygo (budesonide) capsules for the treatment of primary immunoglobulin A nephropathy (IgAN).

The treatment involves adults at risk of rapid disease progression with a specific urine protein-to-creatinine ratio.
READ MORE